Compare KB & IQV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KB | IQV |
|---|---|---|
| Founded | 2008 | 1982 |
| Country | South Korea | United States |
| Employees | N/A | 93000 |
| Industry | Commercial Banks | Biotechnology: Commercial Physical & Biological Resarch |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.2B | 35.1B |
| IPO Year | 2008 | 2013 |
| Metric | KB | IQV |
|---|---|---|
| Price | $118.72 | $260.24 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 16 |
| Target Price | N/A | ★ $227.13 |
| AVG Volume (30 Days) | 192.1K | ★ 1.5M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.31% | N/A |
| EPS Growth | N/A | ★ 4.67 |
| EPS | N/A | ★ 1.61 |
| Revenue | N/A | ★ $9,739,000,000.00 |
| Revenue This Year | $18.22 | $6.77 |
| Revenue Next Year | $3.21 | $5.89 |
| P/E Ratio | ★ $9.90 | $161.38 |
| Revenue Growth | N/A | ★ 41.60 |
| 52 Week Low | $76.31 | $154.50 |
| 52 Week High | $125.66 | $260.40 |
| Indicator | KB | IQV |
|---|---|---|
| Relative Strength Index (RSI) | 51.44 | 72.69 |
| Support Level | $114.71 | $218.57 |
| Resistance Level | $119.71 | N/A |
| Average True Range (ATR) | 2.00 | 7.69 |
| MACD | -0.64 | 0.86 |
| Stochastic Oscillator | 42.79 | 94.28 |
KB Financial Group Inc. is a financial holding company in Korea. The company operations include Kookmin Bank, one of the commercial banks in Korea. The company's subsidiaries collectively engage in a broad range of businesses, including commercial banking, credit cards, asset management, non-life and life insurance, capital markets activities, and international banking and finance. The company's segments include the Banking business, Securities business, Non-life Insurance business, Credit card business, and Life Insurance business. The Group generates the majority of its revenue from the Banking business.
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.